Cancer is predominantly a disease of adults and the elderly. Management of childhood cancer is a multidisciplinary endeavour, including general paediatricians (who rarely see more than two cases of childhood cancer in their entire career) and general practitioners.
and his/her two parents. Childhood cancers are also a model for research, as long-term quality of life and minimisation of sequels in a growing body must be taken into account from the onset. Forty-three per cent of paediatric cancers are haematopoietic malignancies (of which 30% are acute leukaemias and 13% non-Hodgkin's lymphomas).
Solid tumours consist of central nervous system tumours (20%), neuroblastomas of the adrenal gland or the sympathetic nodes (10%), sarcomas of the muscle (7%), renal or Wilm's tumours (6%) and osseous sarcomas, including Ewing sarcomas, and osteosarcomas (5%). Tumours of the retina and liver and several adult-like tumours complete the global picture of childhood cancers.
Management of childhood cancer is a multidisciplinary endeavour, including general paediatricians (who rarely see more than two cases of childhood cancer in their entire career) and general practitioners.
The role of several specialists is fundamental in early treatment of the disease. Pathologists and diagnostic imagers with a solid background in paediatrics are particularly important. Bad news is broken in two steps. It is first discussed where the diagnosis is made, and then in the specialised paediatric unit in which specific treatment will take place.
Whatever the age of the patient, one must first explain the disease to the parents and then to the child. Several interviews will be necessary to help parents manage the initial shock of a cancer diagnosis and proceed to a more constructive emotional phase, where they will be able to ask specific and practical questions. Siblings, family members and school friends will also require specific information and care.
Treatment almost always consists of a combination of chemotherapy and surgery, usually in that order. Radiation therapy is used as rarely as possible during the curative phase due to the likelihood of irreversible sequels in this age group. Brain tumours and retinoblastomas usually require this particular treatment modality, and sarcomas may require radiation for local control or in cases of relapse. Since the 1990s, chemotherapy has become the main tool for treatment of childhood cancer. Treatment design must take into account efficacy, quality of life and long-term sequels.
Childhood cancer therapy can be seen to encompass two lines of enquiry.
The first applies to children with good prognosis, in whom the future is the priority. The important question in this patient group is 'what price should be paid for a cure?' Burkitt's lymphoma (90% cure rate), acute leukaemias and lymphomas (>80% cure rate), Wilm's tumours (80% cure rate), Hodgkin's lymphoma (80% cure rate), localised neuroblastomas (70-90% cure rate), osteosarcomas (75% cure rate) and retinoblastomas (85% cure rate) fall into this category. The second group of patients is made up of those for whom 'cure has a heavy price'. Ewing's sarcomas He also works on new technologies using nanoparticles to improve detection and treatment of solid tumours. Dr Rousseau serves as an expert in medical biotechnologies for the treatment of cancer in several national and international regulatory agencies and scientific societies. He is the co-ordinator of a large EU-funded research consortium dedicated to the immunotherapy of children with cancer (CHILDHOPE). Dr Rousseau received his MD from the University René Descartes, Paris, and his PhD from University Denis Diderot, Paris. He is boardcertified in paediatrics and paediatric oncology. E: roussea@lyon.fnclcc.fr DOI: 10.17925/EOH.2007.0.2.19 (50% cure rate), medulloblastomas (50% overall survival), metastatic neuroblastomas (25% cure rate) and high-grade gliomas (<5% cure rate) fall into this category.
Progress in supportive care has rendered immediate complications manageable, mainly reversible alopecia, nausea and vomiting, pain and blood cell alterations. Long-term toxicity has to be balanced with the risks of disease relapse. Specific toxicities include cardiac toxicity with anthracyclines, deafness with platinum salts, lung toxicities due to radiation therapy and bis-chloroethyl nitrosourea (BCNU), neurocognitive damages with radiation therapy (especially in children below the age of three years), renal toxicity with ifosfamide, methotrexate and platinum salts, sterility and the risk of second tumours (especially with alkylating drugs). This prospective approach has clearly demonstrated its formidable impact on the overall paediatric cancer cure rate, which has risen from a discouraging 0% in the 1960s to over 75% nowadays.
Further information can be found on www.esso-surgeonline.be The Advance Programme will be available on the ESSO website and in printed format as of September 2007.
